Followers | 237 |
Posts | 10817 |
Boards Moderated | 0 |
Alias Born | 07/17/2006 |
![](https://investorshub.advfn.com/uicon/76999.png?cb=1549903350)
Friday, November 23, 2018 7:23:21 AM
To clear up any doubts..I have upmost respect for Dr. Bhatt and am extremely grateful for his support of the company, R-I, and EPA..He is our King Arthur...and out Richard Coeur de Lion rolled into one...
That said I think the Japanese and Dr. Sears and other medical scientists have a pretty good idea on how EPA works..
EPA is a very ancient molecule and it dates back 500 million years being present in early sponges which represent the first form of multi cellular animals...The advantage of being multi cellular is variety any and cooperation...The disadvantage is you present a bigger nutrient target..A greater pile of proteins and fats..So multi cellular animals could not survive against single cell forms which can expand exponentially given a large potential food source (ie the multi cellular animal)...Without some form of defense against microbes.
So the inflammatory system evolved with the very first multi cellular animals.. The inflammatory system was located on the cell membranes which was the facing the invading micro organisms..the "battle ground." The design of the system was foreign material would interact with cell membrane receptors which would then produce inflammatory toxins to combat the invaders...
The system used EPA and was so effective that it still maintains a lot of the features today that were developed 500 million years ago...It its not broke..don't fix it...
Why did it use EPA?...Well the system originated in the primordial oceans and EPA was available being made by micro algae...
A great deal is known about the inflammatory system by certain people..It may be a huge mystery to most cardiologists including the professors...They have been too preoccupied with LDL-C and statins. Which have been a large fraction of their paychecks...
I am not going to go into every aspect of the inflammatory system and how it relates to atherosclerosis and other degenerative disease. It would take much too long...To simplify, the problem is the inflammatory system is a very useful servant, but it is a very poor master..The inflammatory system can get out of control and when it does it can turn on the body and began to use its arsenal of weapons on friendly cells...
The inflammatory system employs chemical warfare using highly toxic substances...That is why there is no gland operating the system..the system is present in all cells except red blood cells.. That is too ensure every cell protects itself and no toxins are distributed through the bloodstream... The inflammatory system is nuanced and has a multitude of actions which include platelet functions and signalling functions...The signalling functions can actually direct normal cells to self destruct committing cellular suicide (apoptosis) which goes on in events like heart attacks and stokes and actually increase the extent of injury...
The inflammatory system does not have set level of activity. Rather it is changing all; the time due to several factors of which diet seems to be the most important...Starvation tends to shut down the system..conserving nutrients for use in physical activity..eg for hunting in periods where food id scarce...Our current problem is too many people are eating too much and this really Jazzes up the inflammatory system which then begins to attack our own cells...EPA tends to slow down/decrease inflammatory activity...
In a perfect world ...our population would eat less and eat healthier..but looking around at all the fatsos..It's not going to happen...We need Vascepa...
":>) JL
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
FEATURED POET Technologies Reports Second Quarter 2024 Financial Results • Aug 15, 2024 8:04 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
ATWEC Reaches Profitability, Announces Massive Earnings Growth, and a Strong Forecast for the Rest of 2024 • ATWT • Aug 15, 2024 7:16 AM